Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Net Margin (2016 - 2025)

Historic Net Margin for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to 9386.67%.

  • Cardiff Oncology's Net Margin fell 21981800.0% to 9386.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 10069.06%, marking a year-over-year decrease of 38274100.0%. This contributed to the annual value of 6655.2% for FY2024, which is 18417300.0% up from last year.
  • Latest data reveals that Cardiff Oncology reported Net Margin of 9386.67% as of Q3 2025, which was down 21981800.0% from 11528.1% recorded in Q2 2025.
  • Cardiff Oncology's Net Margin's 5-year high stood at 4886.34% during Q1 2024, with a 5-year trough of 14863.51% in Q1 2022.
  • Over the past 5 years, Cardiff Oncology's median Net Margin value was 8045.35% (recorded in 2021), while the average stood at 9040.86%.
  • As far as peak fluctuations go, Cardiff Oncology's Net Margin plummeted by -76621200bps in 2022, and later surged by 86425700bps in 2024.
  • Quarter analysis of 5 years shows Cardiff Oncology's Net Margin stood at 7103.76% in 2021, then increased by 4bps to 6799.22% in 2022, then grew by 12bps to 5989.1% in 2023, then crashed by -30bps to 7809.93% in 2024, then fell by -20bps to 9386.67% in 2025.
  • Its last three reported values are 9386.67% in Q3 2025, 11528.1% for Q2 2025, and 12330.28% during Q1 2025.